Lifeward Ltd., a leader in innovative medical technology, announced the successful closing of its public offering, raising approximately $2.6 million. The offering included 4,000,000 ordinary shares and accompanying warrants to purchase an equal number of shares at $0.65 each. The warrants are immediately exercisable and expire in five years. H.C. Wainwright & Co. served as the exclusive placement agent. The proceeds will support Lifeward's commercial efforts, working capital, and general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.